Boothbay Fund Management’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-105,200
| Closed | -$2.64M | – | 2041 |
|
|
2025
Q4 | $2.64M | Sell |
105,200
-32,400
| -24% | -$760K | 0.04% | 484 |
|
|
2025
Q3 | $3.11M | Buy |
+137,600
| New | +$3.21M | 0.05% | 446 |
|
|
2024
Q4 | – | Sell |
-44,000
| Closed | -$1.27M | – | 1479 |
|
|
2024
Q3 | $1.27M | Buy |
+44,000
| New | +$1.63M | 0.03% | 681 |
|
|
2024
Q1 | – | Sell |
-80,400
| Closed | -$4.81M | – | 1567 |
|
|
2023
Q4 | $4.81M | Buy |
80,400
+32,800
| +69% | +$1.66M | 0.12% | 210 |
|
|
2023
Q3 | $1.81M | Buy |
+47,600
| New | +$2.09M | 0.04% | 533 |
|
|
2023
Q2 | – | Sell |
-107,100
| Closed | -$7.06M | – | 1790 |
|
|
2023
Q1 | $7.06M | Buy |
107,100
+37,300
| +53% | +$2.15M | 0.14% | 149 |
|
|
2022
Q4 | $3.61M | Buy |
69,800
+35,000
| +101% | +$1.86M | 0.08% | 347 |
|
|
2022
Q3 | $2.38M | Buy |
34,800
+7,000
| +25% | +$414K | 0.06% | 491 |
|
|
2022
Q2 | $1.26M | Sell |
27,800
-5,600
| -17% | -$255K | 0.03% | 722 |
|
|
2022
Q1 | $1.7M | Buy |
33,400
+11,400
| +52% | +$503K | 0.04% | 641 |
|
|
2021
Q4 | $1.04M | Sell |
22,000
-1,500
| -6% | -$59.1K | 0.02% | 727 |
|
|
2021
Q3 | $775K | Sell |
23,500
-10,600
| -31% | -$596K | 0.02% | 883 |
|
|
2021
Q2 | $2.15M | Buy |
+34,100
| New | +$1.76M | 0.07% | 355 |
|
|
2020
Q1 | – | Sell |
-401
| Closed | -$1.23M | – | 840 |
|
|
2019
Q4 | $1.23M | Buy |
+401
| New | +$11.1K | 0.11% | 265 |
|
Other funds holding APLS
Boothbay Fund Management's APLS Position: Q2 2026 in Review
Boothbay Fund Management sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 183,522 shares — an estimated $7.38M sold.
Boothbay Fund Management first reported a position in APLS in Q4 2018 and held it in 14 quarters. The position peaked at $7.38M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Boothbay Fund Management reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Boothbay Fund Management sold 183,522 Apellis Pharmaceuticals shares in Q2 2026, an estimated $7.38M.
- Boothbay Fund Management first reported a position in Apellis Pharmaceuticals in Q4 2018 and held it in 14 quarters.
- Boothbay Fund Management's Apellis Pharmaceuticals position peaked at $7.38M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.